Hospira (HSP -1.8%) says the FDA's granted pediatric exclusivity for it's alpha-2 agonist...

|By:, SA News Editor

Hospira (HSP -1.8%) says the FDA's granted pediatric exclusivity for it's alpha-2 agonist Precedex injection. The decision extends generic exculsivity by a period of six months after patent expiry.